Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2

Interventions

Magnetic Resonance Spectroscopy 13Temozolomide 11Specimen Handling 8X-Rays 7Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5erdafitinib 4ulixertinib 3trametinib 3larotrectinib 3dabrafenib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2D2C7-(scdsFv)-PE38KDEL 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tazemetostat 1selinexor 1sapanisertib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × D2C7-(scdsFv)-PE38KDEL × 30 days × Clear all
NCT04160494 2026-06-04

D2C7-IT With Atezolizumab for Recurrent Gliomas

Duke University

Phase 1 Active not recruiting
18 enrolled
CNS

Glioblastoma, Glioma

NCT04547777 2026-06-04

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Duke University

Phase 1 Recruiting
90 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡